BR0300599A - Agentes não-peptìdicos da gnrh, composições farmacêuticas e métodos para o seu uso - Google Patents

Agentes não-peptìdicos da gnrh, composições farmacêuticas e métodos para o seu uso

Info

Publication number
BR0300599A
BR0300599A BR0300599-2A BR0300599A BR0300599A BR 0300599 A BR0300599 A BR 0300599A BR 0300599 A BR0300599 A BR 0300599A BR 0300599 A BR0300599 A BR 0300599A
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical compositions
agents
peptide gnrh
gnrh agents
Prior art date
Application number
BR0300599-2A
Other languages
English (en)
Inventor
Lance Christopher Christie
Mark Brian Anderson
Jun Feng
Yufeng Hong
Ved Prakash
Ranjan Jagath Rajapakse
Eileen Valenzuela Tompkins
Haresh Narendra Vazir
Haitao Li
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0300599A publication Critical patent/BR0300599A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"AGENTES NãO-PEPTìDICOS DA GnRH, COMPOSIçõES FARMACêUTICAS E MéTODOS PARA O SEU USO". A presente invenção refere-se a agentes não-peptídicos da GnRH que inibem o efeito do hormónio de liberação da gonadotropina. Estes agentes são úteis para tratar distúrbios reprodutivos em mamíferos e tumores dependentes de hormónios esteróides bem como para regular a fertilidade, onde é indicada a supressão da liberação de gonadotropina.
BR0300599-2A 2002-02-12 2003-02-12 Agentes não-peptìdicos da gnrh, composições farmacêuticas e métodos para o seu uso BR0300599A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35656102P 2002-02-12 2002-02-12

Publications (1)

Publication Number Publication Date
BR0300599A true BR0300599A (pt) 2005-03-29

Family

ID=27613554

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0300599-2A BR0300599A (pt) 2002-02-12 2003-02-12 Agentes não-peptìdicos da gnrh, composições farmacêuticas e métodos para o seu uso

Country Status (10)

Country Link
US (1) US6833372B2 (pt)
EP (1) EP1334972B1 (pt)
JP (1) JP2004002309A (pt)
AT (1) ATE323699T1 (pt)
AU (1) AU2003202115A1 (pt)
BR (1) BR0300599A (pt)
CA (1) CA2418712A1 (pt)
DE (1) DE60304609D1 (pt)
MX (1) MXPA03001320A (pt)
WO (1) WO2003068769A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205307B2 (en) * 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
ES2347544T3 (es) * 2002-03-13 2010-11-02 Janssen Pharmaceutica Nv Inhibidores de histona-desacetilasas.
US7456222B2 (en) 2002-05-17 2008-11-25 Sequella, Inc. Anti tubercular drug: compositions and methods
US20040033986A1 (en) 2002-05-17 2004-02-19 Protopopova Marina Nikolaevna Anti tubercular drug: compositions and methods
US7652039B2 (en) 2002-05-17 2010-01-26 Sequella, Inc. Methods of use and compositions for the diagnosis and treatment of infectious disease
EP1560818A1 (en) * 2002-06-13 2005-08-10 Pfizer Inc. Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
ES2270129T3 (es) * 2002-11-20 2007-04-01 Paradigm Therapeutics Ltd. Compuestos heterociclicos del silicio y su utilizacion en el tratamiento de enfermedades o condiciones asociadas a gnrh (hormona liberadora de gonadotropina).
RU2006105717A (ru) * 2003-07-30 2007-09-20 Зинон Фармасьютиклз Инк. (Ca) Производные пиперазина и их применение в качестве терапевтических агентов
US7884097B2 (en) 2003-09-05 2011-02-08 Sequella, Inc. Methods and compositions comprising diamines as new anti-tubercular therapeutics
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
KR100751314B1 (ko) * 2003-10-14 2007-08-22 삼성에스디아이 주식회사 어드레싱 전력을 최소화한 방전 디스플레이 장치 및 그구동 방법
WO2007000582A1 (en) * 2005-06-28 2007-01-04 Takeda Cambridge Limited Heterocyclic non-peptide gnrh antagonists
CN101258133A (zh) * 2005-09-09 2008-09-03 H.隆德贝克有限公司 嘧啶衍生物和它们作为kcnq钾通道开放剂的用途
US7683058B2 (en) 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
WO2008024398A2 (en) 2006-08-23 2008-02-28 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
TW201008933A (en) * 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
CA2834199C (en) * 2011-07-18 2020-01-07 Merck Patent Gmbh Benzamides as allosteric modulators of the fsh receptor
US20160058895A1 (en) * 2013-04-19 2016-03-03 Oslo Universitetssykehus Hf Radiolabeled gnrh antagonists as pet imaging agents
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
GEP20257732B (en) 2019-11-08 2025-02-10 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
KR20240004241A (ko) 2021-02-09 2024-01-11 제논 파마슈티칼스 인크. 무쾌감증의 치료에 사용하기 위한 전압-게이트 칼륨 채널 오프너
JP2024521450A (ja) * 2021-06-09 2024-05-31 ラディオネティクス オンコロジー，インク． 非ペプチド標的治療およびその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06509075A (ja) 1991-07-01 1994-10-13 ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
US6136781A (en) 1995-04-28 2000-10-24 Takeda Chemical Industries, Ltd. LH-RH receptor antagonists
US5866567A (en) 1995-06-01 1999-02-02 Takeda Chemical Industries, Ltd. Diazepinones, their production and use
IL124613A0 (en) 1995-12-14 1998-12-06 Merck & Co Inc Antagonists of gonadotropin releasing hormone
KR19990072123A (ko) 1995-12-14 1999-09-27 폴락 돈나 엘. 고나도트로핀분비호르몬의길항제및이를포함하는약제학적조성물
CA2240115A1 (en) 1995-12-14 1997-06-19 Wallace T. Ashton Antagonists of gonadotropin releasing hormone
WO1997021704A1 (en) 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6200957B1 (en) 1995-12-14 2001-03-13 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999044987A1 (en) 1998-03-05 1999-09-10 Agouron Pharmaceuticals, Inc. NON-PEPTIDE GnRH AGENTS
US5972898A (en) 1998-03-27 1999-10-26 Abbott Laboratories 3',3-N-bis-substituted macrolide LHRH antagonists
TR200100631T2 (tr) * 1998-08-20 2002-08-21 Agouron Pharmaceuticals,Inc. Peptit-olmayan GnRH maddeleri
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US5981521A (en) 1998-11-13 1999-11-09 Abbott Laboratories Tetrahydroisoquinoline derivatives as LHRH antagonists
FR2793594B1 (fr) 1999-05-11 2001-12-07 Axon Cable Sa Cable passe-bas
DE60022769T2 (de) 1999-10-15 2006-07-06 Neurocrine Biosciences, Inc., San Diego Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen

Also Published As

Publication number Publication date
DE60304609D1 (de) 2006-05-24
EP1334972A1 (en) 2003-08-13
CA2418712A1 (en) 2003-08-12
WO2003068769A1 (en) 2003-08-21
JP2004002309A (ja) 2004-01-08
MXPA03001320A (es) 2003-08-21
US20040053951A1 (en) 2004-03-18
ATE323699T1 (de) 2006-05-15
EP1334972B1 (en) 2006-04-19
US6833372B2 (en) 2004-12-21
AU2003202115A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
BR0300599A (pt) Agentes não-peptìdicos da gnrh, composições farmacêuticas e métodos para o seu uso
LV12732A (en) Non-peptide gnrh agents methods and intermediates for their preparation
LV12631A (en) Non-peptide gnrh agents
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
GT199800042A (es) Nuevos derivados del acido hexanoico.
BR0109983A (pt) Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes
BR0316203A (pt) Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
BRPI0409348B8 (pt) formulações para tratamento de rinossinusite induzida por fungo em um mamífero
BR0215380A (pt) Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo
BR0312024A (pt) Uso de derivados de ciclotiocarbamato no tratamento de condições relacionadas com hormÈnios
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
UY25794A1 (es) Procedimiento para la preparacion de compuestos derivados de adeninas, que son agonistas del receptor de la adenosina a2a
DK279790A (da) Aromatiske steroid-5-alfa-reduktaseinhibitorer
IT1320176B1 (it) Dispersioni solide di principi attivi nitrati.
BR0207827A (pt) Método de preparação de uma micropartìcula homogênea que compreende um inibidor de h+/k+-atpase ácido lábil, micropartìcula, composição farmacêutica, método para prevenir ou tratar uma doença relacionada com o ácido gástrico em um mamìfero, e, uso de uma micropartìcula
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
WO2002098363A3 (en) NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
BR0208694A (pt) Uso de inibidores de cox-2 seletivos para tratamento de incontinência urinária
BR0214643A (pt) Aplicação de um antagonista h1, e um esteróide seguro para tratar rinite
GT199900224A (es) Antagonistas de 5ht1 para terapia antidepresiva.
ES2161714T3 (es) Derivados de 1h-bencimidazol sustituidos por pirroloimidazolilo e imidazopiridinilo como inhibidores de aromatasa.
IT1270612B (it) Derivati eterociclo-condensatori di morfinoidi
MEP13808A (en) Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders
BRPI0520503A2 (pt) composições antiinflamatórias e métodos de uso

Legal Events

Date Code Title Description
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]